PG
MNTA

Patten Group’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Patten Group’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-12,000
Closed -$148K – 643
2016
Q3 		$148K Buy
+12,000
New +$141K 0.07% 201

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Patten Group's MNTA Position: Q4 2016 in Review

Patten Group sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2016, closing a stake of 12,000 shares — an estimated $148K sold.

Patten Group first reported a position in MNTA in Q3 2016 and held it in 1 quarter. The position peaked at $148K in Q3 2016. 160 funds tracked by Wall St. Rank hold MNTA as of Q4 2016.

  • Patten Group reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Patten Group sold 12,000 Momenta Pharmaceuticals, Inc. shares in Q4 2016, an estimated $148K.
  • Patten Group first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
  • Patten Group's Momenta Pharmaceuticals, Inc. position peaked at $148K in Q3 2016.
  • 160 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2016.

Based on Patten Group's 13F filing for Q4 2016, filed 10 Feb 2017.